Lapatinib effect on lapatinib-resistant ErbB2-positive cell line: dose response
Summary:
Analysis of lapatinib-resistant ErbB2-positive cells treated with 0.1 or 1 uM lapatinib. Lapatinib is an EGFR/ErbB2 inhibitor used to treat ErbB2‐positive advanced or metastatic breast cancer. Results provide insight into the mechanisms underlying the development of resistance to lapatinib.
Komurov K, Tseng JT, Muller M, Seviour EG et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol 2012;8:596. PMID: 22864381
